Nutex Health (NUTX) - 2021 Q3 - Quarterly Report

Revenue Performance - Revenue for the three months ended September 30, 2021, was $5,568,757, a significant increase from $350,032 for the same period in 2020, primarily due to the AHP acquisition [151]. - Revenue for the nine months ended September 30, 2021, was $12,873,607, compared to $1,194,250 for the same period in 2020, also driven by the AHP acquisition [151]. Operating Expenses - Operating expenses for the three months ended September 30, 2021, were $2,012,197, compared to $1,636,889 for the same period in 2020 [147]. - General and administrative expenses for the three months ended September 30, 2021, were $1.74 million, up from $698,598 for the same period in 2020, primarily due to the AHP and AHA acquisitions [157]. - Interest expense for the three months ended September 30, 2021, was $1.56 million, compared to $18,252 for the same period in 2020, primarily due to debt related to the acquisition of AHA [162]. - Research and Development expense for the nine months ended September 30, 2021, was $208,615, down from $502,961 for the same period in 2020, due to a reduction in personnel [156]. - The company anticipates additional increases in operating expenses and capital expenditures related to developmental and marketing expenses [173]. Cash Flow and Financing - Cash of $6,011,442 was reported for the nine months ended September 30, 2021, an increase of $5,984,511 from $26,931 as of December 31, 2020 [168]. - Cash used in operating activities for the nine months ended September 30, 2021, was $3,970,719, compared to $1,557,995 for the same period in 2020 [170]. - Cash provided by financing activities for the nine months ended September 30, 2021, was $7,161,652, compared to $472,766 for the same period in 2020 [172]. - The company has no lines of credit or bank financing arrangements, relying on private placements of equity and debt instruments for operations [173]. - Future financing may not be available on acceptable terms, potentially restricting business operations [173]. - Additional issuances of equity or convertible debt securities may result in dilution to current shareholders [173]. Going Concern and Capital Requirements - There is substantial doubt about the company's ability to continue as a going concern, dependent on raising additional capital and generating profitable operations [174]. - Working capital requirements are expected to increase in line with business growth, funded through existing funds and further issuances of securities [173]. - The financial statements have been prepared assuming the company will continue as a going concern, highlighting the need for sufficient capital [174]. - The company may not be able to find alternative sources of cash or generate positive cash flow, adversely affecting business and shareholders [174].